Comparative in vitro activities of XRP 2868, pristinamycin, quinupristin-dalfopristin, vancomycin, daptomycin, linezolid, clarithromycin, telithromycin, clindamycin, and ampicillin against anaerobic gram-positive species, actinomycetes, and lactobacilli.
A comparative study of the in vitro activities of XRP 2868, a new oral streptogramin, against 266 anaerobic gram-positive clinical isolates using the agar dilution method showed that the XRP 2868 MICs for 95% (254 of 266) of isolates were < or =0.5 microg/ml. XRP 2868 MICs for only two strains, one being Clostridium clostridioforme (MIC, 16 microg/ml) and the other being Clostridium difficile (MIC, 32 microg/ml), were >2 microg/ml. Depending on its pharmacokinetics and pharmacodynamics, XRP 2868 has potential for use against infections with gram-positive anaerobes and deserves further clinical evaluation.
Goldstein
Ellie J C
EJ
R. M. Alden Research Laboratory, 2021 Santa Monica Blvd., Suite 740 East, Santa Monica, CA 90404, USA. ejcgmd@aol.com
Citron
Diane M
DM
Merriam
C Vreni
CV
Warren
Yumi A
YA
Tyrrell
Kerin L
KL
Fernandez
Helen T
HT
Bryskier
Andre
A
D039903:Actinobacteria / Q000187:drug effects; D000900:Anti-Bacterial Agents / Q000494:pharmacology*; D001421:Bacteria, Anaerobic / Q000187:drug effects*; D006094:Gram-Positive Bacteria / Q000187:drug effects*; D006801:Humans; D007778:Lactobacillus / Q000187:drug effects; D008826:Microbial Sensitivity Tests; D025361:Streptogramins / Q000494:pharmacology*
D000900:Anti-Bacterial Agents; D025361:Streptogramins